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Low-grade inﬂammation in adipose tissue is recognized as a critical event in the develop-
ment of obesity-related co-morbidities.This chronic inﬂammation is powerfully augmented
through the inﬁltration of macrophages, which together with adipocytes, perpetuate a
vicious cycle of inﬂammatory cell recruitment and secretion of free fatty acids and dele-
terious adipokines that predispose to greater incidence of metabolic complications. In
the last decade, many factors have been identiﬁed to contribute to mounting unresolved
inﬂammation in obese adipose tissue. Among them, pro-inﬂammatory lipid mediators (i.e.,
leukotrienes) derived from the omega-6 polyunsaturated arachidonic acid have been shown
to play a prominent role. Of note, the same lipidmediators that initially trigger the inﬂamma-
tory response also signal its termination by stimulating the formation of anti-inﬂammatory
signals. Resolvins and protectins derived from the omega-3 polyunsaturated docosahex-
aenoic and eicosapentaenoic acids have emerged as a representative family of this novel
class of autacoids with dual anti-inﬂammatory and pro-resolving properties that act as
“stop-signals” of the inﬂammatory response. This review discusses the participation of
these endogenous autacoids in the resolution of adipose tissue inﬂammation, with a spe-
cial emphasis in the amelioration of obesity-related metabolic dysfunctions, namely insulin
resistance and non-alcoholic fatty liver disease.
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RESOLUTION OF INFLAMMATION: CIRCUITS
AND CHEMICAL MEDIATORS
Inﬂammation plays a vital role in host defense against invasive
pathogens and tissue and wound repair. Inﬂammation is part of
the innate immune response and is initiated by a cascade of signals
in response to an infection or injury that leads to the recruitment
of specialized inﬂammatory cells, particularly neutrophils (PMN),
into injured tissue to neutralize and eliminate the injurious stim-
uli (Barton, 2008; Chen and Nuñez, 2010). The innate immune
response not only acts as the ﬁrst line of defense against an insult,
but it also provides the necessary signals to instruct the adaptive
immune system for an effective response to deal with the nox-
ious agent. Although inﬂammation is important in eradication of
pathogens, unresolved, chronic inﬂammation that occurs when
the offending agent is not removed or contained is detrimental to
the host, resulting in tissue damage, ﬁbrosis, and loss of function
(Barton, 2008; Chen and Nuñez, 2010).
Since unresolved inﬂammation is detrimental to the host,
higher organisms have evolved protective mechanisms to ensure
resolution of the inﬂammatory response in a speciﬁc time-limited
manner (Serhan et al., 2008). Once considered a mere passive
process of dilution, resolution is today envisioned as a highly
orchestrated process coordinated by a complex regulatory network
of cells and mediators. This novel insight offers the possibility to
harness resolution factors that clear inﬂammation and use them to
ameliorate the pathologies associated with chronic inﬂammation.
This has the beneﬁt to avoid any unwanted side-effect observed
during the long-term therapy with anti-inﬂammatory drugs such
as cyclooxygenase (COX) inhibitors. COX inhibitors, like aspirin
(ASA) or ibuprofen, can cause gastrointestinal irritation and renal
damage when used in high doses (Wallace and Vong, 2008).
Although at ﬁrst glance selective COX-2 inhibitors looked like
to overcome NSAID toxicity on the gastrointestinal tract, COX-
2 inhibitors as Vioxx were later withdrawn from the market for
their increased risk of cardiovascular thrombotic events (Wallace
and Vong, 2008). For this reason, the search for novel targets and
the identiﬁcation of molecular circuits and chemical mediators
involved in resolution represent a priority in anti-inﬂammatory
therapy.
Among the molecules that facilitate resolution, lipid media-
tors derived from the metabolism of essential polyunsaturated
fatty acids have attracted most attention. The ﬁrst recognized
family of specialized pro-resolving mediators (SPM) was the
lipoxins (LXs). LXs are conjugated trihydroxytetraene-containing
eicosanoids generated from endogenous sources of the omega-6
arachidonic acid (Serhan, 2002). A major route of transcellular
LX biosynthesis is initiated by 15-lipoxygenase (15-LO) forming
15S-hydroxyeicosatetraenoic acid (15S-HETE), which is rapidly
converted to LXA4 by 5-LO (Figure 1; Serhan et al., 1984). Another
major route of transcellular LX biosynthesis is the generation of
15-epi-LXs through a circuit initiated by acetylation of COX-2 by
ASA (Clària and Serhan, 1995). In this route, when ASA inhibits
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FIGURE 1 | Biosynthesis of specialized pro-resolving mediators (SPM).
During the process of resolution of inﬂammation, the omega-6 fatty acid
arachidonic acid (AA) is converted by 15-lipoxygenase (15-LOX) to
15S-hydroxyeicosatetraenoic acid (15S-HETE), which is rapidly converted to
LXA4 and LXB4 by 5-LOX. Formation of 15-epi-LXA4 and 15-epi-LXB4 from
15R-HETE can also occur after acetylation of cyclooxygenase-2 (COX-2) by
aspirin (ASA). Similarly, the omega-3 fatty acid eicosapentaenoic acid (EPA) is
converted into 18-hydroperoxy-EPE (18-HEPE) by aspirin-treated COX-2 or
through cytochrome P450 (CYP450) and subsequently transformed by 5-LOX
into 18S- or 18R-resolvin (Rv) E1. DHA is converted into 17-hydroxy-DHA
(17-HDHA) by 15-LOX which subsequently is transformed by 5-LOX into RvD1
and by epoxidation hydrolysis into protectin D1 (PD1), respectively. Finally,
DHA is transformed by 12-LOX into 14-hydroxy-DHA (14-HDHA) and by 5-LOX
into maresin 1 (MaR1).
prostaglandin (PG) formation in cells bearing a cytokine-induced
COX-2, the resulting ASA-acetylated COX-2 converts arachidonic
acid into 15R-HETE. Subsequently, 15R-HETE is transformed
by 5-LO of activated neutrophils into 15-epi-LXs, which carry
the carbon-15 alcohol in the R conﬁguration, instead of the S
as in the native LXs (Figure 1; Clària and Serhan, 1995). These
SPM act as “stop-signals” for inﬂammation and inhibit leukocyte
chemotaxis, adhesion to and transmigration across endothelial
monolayers in response to LTB4 (Serhan et al., 2008). LX stable
analogs inhibit in vivo LTB4-induced leukocyte rolling, adher-
ence, margination and extravasation and when applied topically
to mouse ears they dramatically inhibit leukocyte inﬁltration and
vascular permeability (Serhan et al., 2008).
Resolvins are the second family of SPM with recognized
anti-inﬂammatory and pro-resolving properties. Resolvins are
endogenous lipid mediators generated from the omega-3 docosa-
hexaenoic acid (DHA) and eicosapentaenoic acid (EPA). They
were initially identiﬁed using a lipidomics-based approach that
combined liquid chromatography and tandem mass spectrometry
within self-limited inﬂammatory exudates captured during the
“spontaneous resolution” phase of acute inﬂammation (Serhan
et al., 2000, 2002). Resolvins are classiﬁed into D- and E-series
in accordance with their biosynthetic precursor, either DHA or
EPA, respectively. Schematically, resolvin biosynthesis is initi-
ated by 15-LO which transforms endogenous sources of DHA
into 17S-hydroxy-DHA which is further transformed by leuko-
cyte 5-LO into resolvin (Rv) D1 and RvD2 (Figure 1; Hong
et al., 2003). Endothelial cells expressing COX-2 treated with
aspirin also transform DHA into 17R-hydroxy-DHA which is
further converted by 5-LO into 17R-RvD1 (Figure 1; Ser-
han et al., 2000, 2002). DHA can also be metabolized into a
dihydroxy-containing derivative via an intermediate epoxide that
opens via hydrolysis and subsequent rearrangements to form
protectin (PD) 1 (Figure 1; Serhan et al., 2000, 2002; Hong
et al., 2003). Similarly, RvE1 biosynthesis is initiated when EPA
is converted to 18-hydroperoxy-EPE by aspirin-treated COX-2
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or through cytochrome P450 activity (Serhan et al., 2000;
Haas-Stapleton et al., 2007). By transcellular biosynthesis, 18-
hydroperoxy-EPE is transformed by 5-LO of neighboring leuko-
cytes into RvE1 via a 5(6)epoxide intermediate (Figure 1; Serhan
et al., 2000, 2002).
RvD1, RvD2, PD1, and RvE1 are potent SPM, which contrary
to their metabolic substrates, DHA and EPA, exert their biological
actions at the nanomolar range. Indeed, the potency of these SPM
is notable with concentrations as low as 10 nM producing a 50%
reduction in PMN transmigration. Two receptors (ALX/FPR2 and
GPR32) have been shown to transmit RvD1 signals (Krishnamoor-
thy et al., 2010), whereas a G-protein coupled receptor (ChemR23)
signals for RvE1 (Arita et al., 2005a). The full structural elucida-
tion, stereochemical assignment and biological actions for these
compounds were ﬁrst completed in RvE1. RvE1 was readily shown
to decrease PMN inﬁltration and T cell migration, reduce tumor
necrosis factor (TNF) α and IFNγ secretion, inhibit chemokine
formation, and block interleukin (IL)-1-induced NF-κB activa-
tion (Schwab et al., 2007; Bannenberg and Serhan, 2010). RvE1
was also shown to stimulate macrophage phagocytosis of apop-
totic PMN and to be a potent counter-regulator of L-selectin
expression (Schwab et al., 2007; Dona et al., 2008). RvE1 dis-
played potent anti-inﬂammatory actions in vivo, protecting mice
against experimental periodontitis, colitis, peritonitis, and brain
ischemia-reperfusion (Arita et al., 2005b; Bannenberg and Serhan,
2010). A RvE1-initiated resolution program for allergic airway
response was identiﬁed by Haworth et al. (2008). Similarly, RvD1
and RvD2 were reported to reduce inﬂammatory pain, block
IL-1β transcripts induced by TNFα in microglial cells and func-
tion as potent regulators limiting PMN inﬁltration into inﬂamed
brain, skin, and peritoneum (Hong et al., 2003; Sun et al., 2007).
RvD2 in particular has been shown to be a potent endogenous
regulator of excessive inﬂammatory responses in mice with micro-
bial sepsis (Spite et al., 2009). Moreover, PD1 has been reported
to exert protective actions in acute models of inﬂammation by
blocking PMN migration and inﬁltration into the inﬂamma-
tory site (Serhan et al., 2006). Finally, these SPM expedite the
resolution process by paving the way for monocyte migration
and their differentiation to phagocytosing macrophages, which
remove dead cells (efferocytosis) and then terminate the inﬂam-
matory response by promotingmacrophage efﬂux into lymphatics
(Schif-Zuck et al., 2011).
RESOLUTION OF ADIPOSE TISSUE
INFLAMMATION IN OBESITY
Abdominal obesity and insulin resistance are the predominant
underlying risk factors for the metabolic syndrome and related
co-morbidities such as type 2 diabetes, dyslipidemia, and non-
alcoholic fatty liver disease (Elks and Francis, 2010). A wealth of
evidence indicates that metabolic disorders associated with obe-
sity are initiated by the presence of a chronic “low-grade” state
of inﬂammation in the adipose tissue (Ferrante, 2007; Elks and
Francis, 2010). This “low-grade” inﬂammatory state is aggravated
by the recruitment of inﬂammatory cells, mainly macrophages
in the adipose tissue (Ferrante, 2007; Elks and Francis, 2010).
As a consequence of this unresolved inﬂammatory response, the
production of pro-inﬂammatory adipokines [i.e., IL-6, TNFα,
and monocyte chemotactic protein-1 (MCP-1)] is increased while
the secretion of adiponectin, an anti-inﬂammatory and insulin-
sensitizing adipokine, is reduced (Figure 2A; Ferrante, 2007; Elks
and Francis, 2010). In addition to adipokines, the formation of
pro- and anti-inﬂammatory lipid mediators is also severely dereg-
ulated in obesity. Indeed, we have recently demonstrated that the
production of SPM (i.e., RvD1 and PD1 and the metabolic pre-
cursors 14-HDHA, 17-HDHA, 18-HEPE) is deﬁcient in inﬂamed
obese adipose tissue (Clària et al., 2012). Whether the response to
these mediators is also impaired and whether this SPM deﬁcit is a
generalized property of obese tissues are open questions that need
to be addressed.
Adipose tissue inﬂammation is also driven by the activation
of classical pro-inﬂammatory pathways such as arachidonate 5-
LO. Indeed, over-expression of FLAP is a common ﬁnding in
adipose tissue of patients and animals with obesity and insulin
resistance (Kaaman et al., 2006; Horrillo et al., 2010). Moreover,
linkage studies have identiﬁed 5-LO as a gene with pleiotropic
actions on adipose fat accumulation and pancreatic function
(Mehrabian et al., 2008). The ability of adipose tissue to generate
5-LO-derived products has recently been challenged by Horrillo
et al. (2010). These authors have demonstrated the presence of
all enzymes necessary for the formation of 5-LO products (5-
LO, FLAP, LTA4 hydrolase, and LTC4 synthase) as well as all
receptors involved in leukotriene (LT) signaling (BLT1, BLT2,
CysLT1, and CysLT2) in adipose tissue of both lean and obese
mice (Horrillo et al., 2010). Importantly, adipose tissue samples
from obese mice showed increased formation of 5-LO prod-
ucts, mainly LTB4 (Horrillo et al., 2010). Similar ﬁndings have
been reported in visceral adipose tissue from obese Zucker rats
(Chakrabarti et al., 2011). An important observation of the study
by Horrillo et al. (2010) was that LTB4 unequivocally triggered an
inﬂammatory response in adipose tissue by inducing the nuclear
translocation of p50 and p65 subunits of NF-κB. Secondary to
LTB4-induced NF-κB activation, there was an enhanced release of
MCP-1 and IL-6, which directly connect adipose tissue inﬂamma-
tion with insulin resistance and hepatic steatosis (Horrillo et al.,
2010). The physiological consequences of these changes in adi-
pose tissue function were corroborated in vivo by observing that
either pharmacological inhibition of the 5-LO pathway or genetic
deletion of Alox5, the gene coding for 5-LO, alleviate insulin resis-
tance and hepatic steatosis in obese animals (Horrillo et al., 2010;
Martínez-Clemente et al., 2010).
In sharp contrast to the pro-inﬂammatory actions for the
most part of omega-6-derived products, omega-3-derived lipid
mediators act as “braking signals” of the persistent vicious
cycle leading to unremitting inﬂammation in obese adipose
tissue. Endres et al. (1989) were the ﬁrst to demonstrate anti-
inﬂammatory properties of the omega-3 fatty acids. Since then,
supplementation of omega-3 fatty acids has proven to exert
overall beneﬁts in obesity and metabolic syndrome. In a recent
series of experiments, González-Périz et al. (2009) have demon-
strated that administration of an omega-3-enriched diet to ob/ob
mice, an experimental model of obesity and fatty liver dis-
ease, resulted in increased adiponectin levels and reduced insulin
resistance and hepatic steatosis. These changes occurred in par-
allel with augmented formation of omega-3-derived SPM in
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FIGURE 2 | (A) Schematic overview summarizing the cross-talk between
macrophages and adipocytes in obese adipose tissue. Obese adipose tissue
shows a remarkable inﬁltration of macrophages which form “crown-like”
structures that surround necrotic adipocytes. This recruited macrophages
together with hypertrophy and/or hyperplasia of adipocytes produce an
aberrant release of pro-inﬂammatory adipokines [tumor necrosis factor (TNF)
α, interleukin (IL)-6, IL-1β, and monocyte chemotactic protein-1 (MCP-1)] that
leads to insulin resistance. Unbalanced formation of pro-inﬂammatory
leukotriene (LT) B4 and leptin accompanied by a deﬁcit in anti-inﬂammatory
mediators [i.e., resolvin (Rv) D1, protectin (PD) 1, and adiponectin] contributes
to a state of unresolved inﬂammation in obese adipose tissue. (B) Schematic
representation of the protective actions of specialized omega-3-derived
mediators on liver and adipose tissue. Eicosapentaenoic acid (EPA) is
converted into 18-hydroperoxy-EPE (18-HEPE) and resolvin (Rv) E1, whereas
DHA is converted into 17-hydroxy-DHA (17-HDHA) and RvD1 and protectin D1
(PD1). In the liver, these specialized pro-resolving mediators (SPM) protect
hepatocytes from DNA damage and oxidative stress and dampen
inﬂammation by inhibiting TNFα, LTB4, and cyclooxygenase-2 (COX-2) in
Kupffer cells. In adipose tissue, SPM exert insulin sensitizing actions by
up-regulating adiponectin, AMP-activated protein kinase (AMPK), insulin
receptor signaling-1 (IRS-1) and glucose transporter-4 (GLUT-4) in adipocytes
and promoting M2 polarization [arginase 1 (Arg1), IL-10, chitinase 3-like 3
(Ym1), resistin-like molecule (RELM)-α, and CD206] while inhibiting M1
markers (TNFα, IL-6, and MCP-1) in macrophages.
adipose tissue, while formation of the omega-6-derived products
PGE2, 5-HETE, and LTB4 was signiﬁcantly inhibited (González-
Périz et al., 2009). Along these lines, intraperitoneal injection of
nanogram doses of RvE1 elicited signiﬁcant insulin-sensitizing
effects by inducing adiponectin, glucose transporter-4 (GLUT-4)
and insulin receptor signaling-1 (IRS-1) expression in adipose tis-
sue and conferred signiﬁcant protection against hepatic steatosis
(González-Périz et al., 2009). Similarly, in leptin receptor-deﬁcient
(db/db) obese and diabetic mice, nanogram doses of RvD1
improved glucose tolerance, decreased fasting blood glucose, and
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increased insulin-stimulated Akt phosphorylation while reduc-
ing the formation of crown-like structures rich in inﬂammatory
macrophages in adipose tissue (Hellmann et al., 2011). Recently,
similar beneﬁcial actions have been described for LXA4 in
an experimental model of age-associated adipose inﬂammation
(Börgeson et al., 2012).
Omega-3-derived mediators can also induce changes in the
status of macrophage polarization toward a pro-resolution phe-
notype. Tissue macrophages are phenotypically heterogeneous
and display an extensive receptor repertoire and a versatile
biosynthetic capacity that confer them the plasticity to adapt to
different tissue microenvironments (Gordon and Taylor, 2005).
Macrophages are broadly characterized by their activation (polar-
ization) state according to the M1/M2 classiﬁcation system
(Mantovani et al., 2007). In this classiﬁcation, the M1 designa-
tion is reserved for classically activated macrophages following
stimulation with IFNγ and LPS, whereas the M2 designation is
applied to the alternatively activated macrophages after in vitro
stimulation with IL-4 and IL-13. M1 macrophages secrete high
amounts of TNFα, IL-1β, and IL-6, whereas M2 macrophages
dampen pro-inﬂammatory cytokine levels and promote resolu-
tion of inﬂammation and tissue repair (Gordon and Taylor, 2005).
M1/M2 macrophage polarization can be monitored by assess-
ing the expression of selected markers. M1-associated markers
include inducible nitric oxide synthase (iNOS) and classical pro-
inﬂammatory mediators such as TNFα, IL-1β, IL-6, and MCP-1.
In contrast, established M2 markers include scavenger, man-
nose (CD206) and galactose (Mgl-1) receptors, arginase 1, IL-10,
chitinases Ym1 and Ym2, and resistin-like molecule (RELM)-α
(Martínez et al., 2009).
In a recent study, Titos et al. (2011) have demonstrated that
RvD1 consistently induced M2 polarization in adipose tissue
macrophages. These investigators ﬁrst noticed that DHA did not
modify the total number of macrophages in obese adipose tis-
sue, but markedly reduced the percentage of CD11bhigh/F4/80high
expressing cells in parallel with the emergence of low-expressing
CD11b/F4/80 macrophages, suggesting a phenotypic switch in
macrophage polarization. Indeed, these investigators further
demonstrated that DHA and RvD1 up-regulated a complete
panel of M2 markers including IL-10, CD206, RELM-α, and
Ym1, and remarkably stimulated arginase 1 expression while
promoting non-phlogistic macrophage phagocytosis and atten-
uating IFNγ/LPS-induced Th1 cytokine secretion (Titos et al.,
2011). These results were in agreement with those reported by
Hellmann et al. (2011), who showed the ability of RvD1 to
improve insulin resistance in obese-diabetic mice, by reducing
macrophage F4/80+CD11c+ cell accumulation and increasing
the percentage of positive F4/80 cells expressing the M2 marker
Mgl-1 in adipose tissue. The ability of resolvins to modify
macrophage plasticity has also been demonstrated by Schif-Zuck
et al. (2011), who reported that administration of RvD1 and
RvE1 to peritonitis-affected mice enhanced the appearance of
CD11blow macrophages by reducing the number of engulfment-
related events required for macrophage deactivation and by
reducing the ability of peritoneal macrophages to produce pro-
inﬂammatory cytokines upon LPS stimulation. As the majority
of macrophages that accumulate in obese adipose tissue are M1
inﬂammatory type, these ﬁndings are a strong argument in favor of
the pro-resolution actions of omega-3-derived mediators in obese
adipose tissue.
RESOLUTION OF OBESITY-INDUCED STEATOHEPATITIS
Lipids, adipokines, and other soluble factors released by inﬂamed
adipose tissue have a direct impact on other insulin-sensitive tis-
sues, especially on the liver. In fact, both adipose and hepatic
tissues have immediate access to a vast network of blood vessels
that implicate a direct connection between these two tissues. This
connection is exempliﬁed by the observation that the circulat-
ing fatty acid pool derived from fat is the primary contributor to
hepatic steatosis, the initial stage in non-alcoholic steatohepati-
tis (Donnelly et al., 2005). In this context, adiponectin represents
a paradigmatic example of the direct control of adipokines on
liver function. Adiponectin, which is an adipokine with potent
anti-inﬂammatory and insulin-sensitizing properties, is a hep-
atoprotective adipokine lowering hepatic steatosis and insulin
resistance and preventing liver ﬁbrosis (Tilg, 2010). Impor-
tantly, adiponectin is able to up-regulate the RvE1 receptor
ChemR23 in primary human adipocytes, which expression is seri-
ously compromised in human and rodent fatty liver (Wanninger
et al., 2012).
To better appreciate how adipose tissue inﬂuences hepatic
inﬂammation and the progression fromsteatosis to steatohepatitis,
it is necessary to fully understand the complex cellular architecture
of the liver. The hepatic tissue is arranged in a peculiar fenestrated
capillary network known as the hepatic sinusoid (Wisse et al.,
1996). The morphological features of the hepatic sinusoid provide
a unique environment where each single hepatocyte is in close
contact with other hepatocytes as well as with non-parenchymal
sinusoidal liver cells, including Kupffer cells, endothelial cells, and
hepatic stellate cells (Wisse et al., 1996). In terms of inﬂamma-
tion, Kupffer cells, the liver resident macrophages, play the most
relevant role and have been classically considered the major sinu-
soidal cell type involved in hepatic eicosanoid formation (Decker,
1990). Indeed, Kupffer cells express COX-1, COX-2, and 5-LO
and generate relevant amounts of PGE2, PGI2, PGF2α, PGD2,
LTB4, and LTC4/LTD4/LTE4 (Decker, 1990; Titos et al., 2000,
2003). These resident hepatic macrophages are also able to gen-
erate LXA4 from endogenous sources of arachidonic acid or by
transcellular biosynthesis from 15S-HETE released by nearby 15-
LO-containing hepatocytes (Clària and Planagumà, 2005). Unlike
LTB4 and PGE2, Kupffer cell-derived LXA4 down-regulates the
cytokine–chemokine axis in adjacent hepatocytes (Planagumà
et al., 2002).
Liver tissue is also a rich source of omega-3-derived SPM, such
as PD1 and its intermediate precursor 17S-HDHA (González-
Périz et al., 2006). These SPM produced an amelioration of
necroinﬂammatory liver injury, an effect that was associated with
a decrease in hepatic COX-2 expression and PGE2 formation and
reduced genotoxic DNA damage and oxidative stress in isolated
hepatocytes (González-Périz et al., 2006). More important, these
SPM reduced TNFα release in macrophages, recognized as the
predominant effector cells involved in the inﬂammatory cascade
leading to hepatocyte damage. A signiﬁcant down-regulation of
5-LO protein expression was also noticed in macrophages treated
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with 17S-HDHA and in liver tissue from mice receiving DHA in
the diet (González-Périz et al., 2006). This is relevant because the
presence of an active 5-LOpathway in the liver is restricted toKupf-
fer cells and its inhibition is linked to lower necroinﬂammatory
liver injury and ﬁbrosis (Titos et al., 2000, 2003, 2005).
SUMMARY
Obesity and the associated metabolic disorders are characterized
by the presence of a chronic “low-grade” inﬂammatory response
in insulin sensitive tissues, in particular adipose tissue and liver.
The mechanisms explaining this observation are unknown but
unremitting inﬂammation is likely to be the consequence of an
impaired resolution. Resolution of inﬂammation (the so-called,
“catabasis”) is not a passive process that simply occurs when
the stimulus disappears, but it is a highly regulated process that
requires the coordinated action of pro-resolution SPM. Among
these, in recent years we have witnessed an emergence of a num-
ber of SPM carrying both anti-inﬂammatory and pro-resolution
properties, namely LXs, resolvins, and protectins. A schematic
representation of the actions of these lipid mediators on adipose
tissue and liver cells is shown in Figure 2B. In summation, these
autacoids enhance inﬂamed adipose tissue catabasis and provide
powerful templates for the design of novel therapies to combat the
progression of metabolic complications associated with obesity.
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